N-Acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats

Basit Öğe Kaydı
dc.authorid, ahmet/0000-0001-6274-5700
dc.authoriddemir, ibrahim halil/0000-0002-9079-9818
dc.contributor.authorArica, V.
dc.contributor.authorDemir, I. H.
dc.contributor.authorTutanc, M.
dc.contributor.authorBasarslan, F.
dc.contributor.authorArica, S.
dc.contributor.authorKarcioglu, M.
dc.contributor.authorOzturk, H.
dc.date.accessioned2024-09-18T20:15:22Z
dc.date.available2024-09-18T20:15:22Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThis study is designed to observe the effects of N-acetylcysteine (NAC) on doxorubucine-induced cardiac toxicity in rats both histologically and biochemically. Totally 32 rats divided equally into four groups were studied. The first group received only 200 mg/kg NAC intraperitoneal (i.p.) once every 24 h for 5 days (group 1); the second group received 20 mg/kg doxorubucine (DOX) i.p. single dose plus NAC 200 mg/kg i.p. once every 24 h for 5 days (group 2); the third group received DOX 20 mg/kg DOX i.p. single dose (group 3) and the fourth group, which is also the control group, received saline (group 4). Following 24 h of the final dose, blood samples were drawn from a portal vein and heart tissue were obtained. Tissue thiobarbituric acid reactive substance (TBARS) and nitric oxide (NO) levels were highest in the DOX group. In the DOX-treated rats, serum TBARS, NO, aspartate transaminase, lactate dehydrogenase and creatine kinase levels were highest when compared with other groups. Except for serum superoxide dismutase levels, all other parameters differed significantly between the DOX plus NAC group and the DOX group. In the DOX plus NAC group, general architecture was preserved better than the DOX group and myofibril loss was minimal compared with the DOX group. NAC demonstrated, both biochemically and histologically, to be effective in the prevention of DOX-induced cardiotoxicity in rat models. Evaluation of NAC's effect on DOX toxicity warrants further clinical trials on cancer patients.en_US
dc.identifier.doi10.1177/0960327112467043
dc.identifier.endpage661en_US
dc.identifier.issn0960-3271
dc.identifier.issn1477-0903
dc.identifier.issue6en_US
dc.identifier.pmid23424206en_US
dc.identifier.scopus2-s2.0-84878308423en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage655en_US
dc.identifier.urihttps://doi.org/10.1177/0960327112467043
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9587
dc.identifier.volume32en_US
dc.identifier.wosWOS:000319228700010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofHuman & Experimental Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDoxorubucineen_US
dc.subjectcardiac toxicityen_US
dc.subjectN-acetylcysteineen_US
dc.titleN-Acetylcysteine prevents doxorubucine-induced cardiotoxicity in ratsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
368.58 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu